Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $768

Benzinga · 2d ago
Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $767 to $768.